Search results for
23 items
Equality and Human Rights consultation - NICE NG 14 - Melanoma: assessment and management
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1st July 2006,
Equality and Human Rights Consultation - NICE TA - Talimogene Laherparepvec for Treating Metastatic Melanoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Nivolumab in combination with ipilimumab for treating advanced melanoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Nivolumab for treating advanced (unresectable or metastatic) melanoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Pembrolizumab for treating advanced melanoma previously untreated with ipilimumab
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) melanoma.
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights consultation - NICE TA - Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006
Equality and Human Rights Consultation - NICE TA - Dabrafenib in Combination with Trametinib for Adjuvant Treatment of Resected BRAF V600 Positive Malignant Melanoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Skin cancer prevention
Skin cancer is the most common form of cancer in Northern Ireland with the incidences of both non-melanoma and malignant melanoma increasing over
Health Minister launches new service for skin cancer patients
Health Minister Robin Swann has launched a new mole mapping service at the Ulster Hospital, Dundonald.
Sunbeds policy
Skin cancer rates in Northern Ireland have trebled in the last 25 years. It is now the most common form of cancer here and accounts for 28 per cent
NICE - Endorsed Technology Appraisals 2018/2019
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health
Major New Cancer Research Report Published Today
The report Pathways to a Cancer Diagnosis: monitoring variation in the patient journey across NI, 2012-2016 provides, for the first time, a
NICE - Endorsed Technology Appraisals 2012/2013
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health
NICE - Endorsed Technology Appraisals 2016/2017
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health
NICE - Endorsed Technology Appraisals 2014/2015
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health
NICE - Endorsed Technology Appraisals 2015/2016
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health
NICE - Endorsed Technology Appraisals 2021/2022
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health
NICE - Endorsed Clinical Guidelines 2010/2011
The following NICE Clinical Guidelines and Cancer Service Guidance were endorsed by DoH during 2010/2011